Ending the Cosmetics Subsidiary’s Business Activities and Transferring the Domestic Placenta Business
First written in FY2025. 6 of 10 entries say "Achieved", first in 2026-05-13. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AchievedAnnual report
「The cosmetics business involving placenta products, the core products of the domestic business, was transferred to the consolidated subsidiary Nippon Preventive Medicine Co., Ltd. on 1 March 2026. BB Laboratories Co., Ltd. subsequently terminated its business activities on 31 March 2026.」
BB Laboratories’ withdrawal from China and termination of its business activities, and the transfer of the domestic placenta cosmetics business to Nippon Preventive Medicine, were completed. - FY2026-H1AdvancedAnnual report
「BB Laboratories Co., Ltd. has decided to withdraw from the Chinese market and terminate its business activities by the end of March 2026, and is proceeding with the closing of its business in preparation for dissolution and liquidation. The cosmetics business involving placenta products, the core products of the domestic business, is also being transferred expeditiously to the consolidated subsidiary Nippon Preventive Medicine Co., Ltd.」
The Company is proceeding with the business closing and the transfer of the domestic placenta business to Nippon Preventive Medicine in preparation for withdrawal from the Chinese market and the termination of BB Laboratories’ business activities by the end of March 2026. In addition, the transfer of the related trademark rights and other assets was completed on 21 August 2025. - FY2025First statedAnnual report
「At a meeting of the Board of Directors held on 18 August 2025, the Company resolved to withdraw its consolidated subsidiary BB Laboratories Co., Ltd. (hereinafter, “Bbl”) from the Chinese market and terminate all of its business activities, and approved the execution of an agreement to transfer the trademark rights held by Bbl relating to the “Bb Laboratories” brand, excluding those relating to “placenta” (hereinafter, the “Trademarks”). Bbl is scheduled to dissolve and be liquidated after terminating its business activities. However, the cosmetics business involving placenta products, the core products of the domestic business, will be transferred to and continue under the Company’s consolidated subsidiary, Nippon Preventive Medicine Co., Ltd.」
On 18 August 2025, the Company decided to withdraw from the Chinese market, terminate all business activities of BB Laboratories, and transfer the brand trademark rights. Business activities are scheduled to end on 31 March 2026, and the domestic placenta business will be transferred to Nippon Preventive Medicine.